Cannabis and Apixaban (Eliquis)
Brand names: Eliquis
Important Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice. Do not start, stop, or modify your use of Apixaban or cannabis without consulting your doctor or pharmacist. If you experience adverse effects, seek immediate medical attention. Individual responses to drug combinations vary significantly.
Overview
Apixaban is a direct oral anticoagulant (blood thinner) prescribed to prevent blood clots, stroke in atrial fibrillation, and treat deep vein thrombosis or pulmonary embolism. The interaction with cannabis, particularly CBD, is classified as high risk because of the potentially life-threatening consequence: increased bleeding. Apixaban relies heavily on CYP3A4 for its metabolism, and CBD's inhibition of this enzyme can elevate apixaban levels in the blood, intensifying its anticoagulant effect beyond the intended therapeutic range. Unlike warfarin, apixaban does not have routine blood monitoring in standard clinical practice, making it harder to detect when levels are too high. This means the interaction could go unrecognized until a bleeding event occurs. Even minor increases in apixaban levels can shift the balance from therapeutic anticoagulation to a dangerous bleeding risk. Given that the patients who take apixaban often have serious underlying conditions (atrial fibrillation, prior blood clots), the stakes of this interaction are particularly high.
How They Interact
Apixaban is a direct Factor Xa inhibitor that is metabolized primarily by CYP3A4, with additional contributions from CYP1A2, CYP2C8, CYP2C9, and CYP2J2. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) drug transporters. CBD is a moderate-to-potent inhibitor of CYP3A4 and has been shown to inhibit P-gp as well. The dual inhibition of both the metabolic enzyme and the efflux transporter could significantly increase apixaban's bioavailability and reduce its clearance, leading to elevated plasma concentrations. Higher apixaban levels directly correlate with increased risk of bleeding complications, including gastrointestinal hemorrhage, intracranial bleeding, and excessive bruising. THC is a CYP3A4 substrate but does not significantly inhibit it; however, THC's acute cardiovascular effects (blood pressure changes) in anticoagulated patients add an additional layer of risk.
Cannabinoid-Specific Interactions
| Cannabinoid | Interaction with Apixaban |
|---|---|
| CBD | CBD inhibits both CYP3A4 and P-glycoprotein, the primary enzyme and transporter responsible for apixaban elimination. This dual inhibition can significantly increase apixaban blood levels, substantially raising the risk of serious or life-threatening bleeding events. This is a clinically important, high-risk interaction. |
| THC | THC has minimal direct pharmacokinetic interaction with apixaban. However, THC-induced changes in blood pressure and occasional falls related to impaired coordination could be particularly dangerous in anticoagulated patients, as even minor trauma can cause significant bleeding. |
Symptoms to Watch For
- ⚠Unusual or excessive bruising
- ⚠Prolonged bleeding from cuts or wounds
- ⚠Blood in urine (pink or red) or stool (dark, tarry)
- ⚠Coughing up blood or vomiting blood
- ⚠Severe, unexplained headache (possible intracranial bleeding)
Recommendations
- 1Inform your prescriber immediately if you use any cannabis products, especially CBD, while taking apixaban.
- 2Avoid regular CBD use while on apixaban unless explicitly approved and monitored by your healthcare provider.
- 3If you must use cannabis, THC-dominant products without significant CBD content carry lower interaction risk, but still require caution.
- 4Report any signs of unusual bleeding immediately to your doctor — do not wait for your next appointment.
- 5Never adjust your apixaban dose on your own. Dose changes must be managed by your physician.
Research Summary
The FDA's prescribing information for apixaban (Eliquis) specifically warns that strong CYP3A4 and P-gp dual inhibitors can increase apixaban exposure and bleeding risk, recommending dose reduction when these are co-administered. While CBD is classified as a moderate rather than strong CYP3A4 inhibitor, it also inhibits P-gp, creating a dual-inhibition scenario analogous to the strong inhibitor warning. A 2020 case report in the Journal of Pharmacy Practice described a patient on apixaban who developed significant bruising after starting a CBD supplement. Pharmacokinetic modeling studies have estimated that moderate CYP3A4 inhibitors can increase apixaban AUC by 1.5 to 2-fold, which is clinically meaningful for a drug with a narrow therapeutic window between efficacy and bleeding.
Frequently Asked Questions
Can I use CBD oil while taking Eliquis?
This combination carries significant risk. CBD inhibits the enzymes and transporters that clear apixaban from your body, which can increase your bleeding risk substantially. You should discuss any CBD use with your prescriber, who may need to adjust your dose or increase monitoring.
What should I do if I notice unusual bruising while using cannabis and Eliquis?
Contact your healthcare provider immediately. Unusual bruising, prolonged bleeding from minor cuts, blood in urine or stool, or unexplained headaches can all be signs of excessive anticoagulation. Do not wait for these symptoms to resolve on their own.
Is THC-only cannabis safer with Eliquis than CBD?
THC has a lower pharmacokinetic interaction risk with apixaban compared to CBD, as it does not significantly inhibit CYP3A4 or P-glycoprotein. However, THC's effects on coordination and blood pressure still pose indirect risks for anticoagulated patients, so caution is still warranted.
Should I stop taking Eliquis if I use cannabis?
Never stop taking apixaban without consulting your doctor. Stopping your blood thinner abruptly can lead to life-threatening blood clots or stroke. Instead, discuss your cannabis use honestly with your prescriber so they can make informed decisions about your care.